skin-diseases-and-microbiology-2016_posters-abstracts

15 / 18

Volume 4, Issue 7(Suppl) J Infect Dis Ther 2016
ISSN: 2332-0877, JIDT an open access journal
Page 61
Skin Diseases & Microbiology 2016
October 03-05, 2016
conferenceseries.com
October 03-05, 2016 Vancouver, Canada
International Conference on
Infectious Diseases, Diagnostic Microbiology &
Dermatologists Summit on Skin Infections
Public health intervention to address the burden of dermatological complications of diabetes-related foot
disorder in community-dwellers living in rural Ecuador
Elizabeth Cusick
Stony Brook University School of Medicine, USA
Diabetes-related foot disorders (DRFD) are among the most feared complications of diabetes mellitus. Foot and ankle ulcerations
are the most common causes of non-traumatic amputations in the world. As the majority of these amputations are preventable,
efforts should be directed to early detection of individuals at risk, particularly in underserved populations where people are often
uninformed of the tremendous risks posed by ulcerative lesions in the feet and ankles. A population-based cohort study to assess
the burden of DRFD dermatological sequale was conducted in Atahualpa, a rural Ecuadorian village, by identifying residents aged
≥40 years with diabetes mellitus using ankle brachial index to determine presence of peripheral arterial disease, foot examination
to assess skin changes, dry skin, ulcerations, fissures and the Michigan Neuropathy Screening Instrument to estimate peripheral
neuropathy. Ulcers of the foot/ankle and amputations (always preceded by ulcers) were noticed in 7% of participants and 60% of
individuals without ulcers or amputations were at moderate to high risk of developing active diabetic foot disease. These ulcers
had been previously recognized and treated in less than 20% of patients. Public health strategies directed to reduce the incidence of
catastrophic consequences such as lower limb amputations, are urgently needed to improve the quality of life of millions of persons with
diabetes mellitus living in these underserved populations. As a result, weekly community health workshops have been implemented
in Atahualpa to educate the high-risk population about the prevention, recognition and care for dermatological manifestations of
DRFD to prevent amputation.
A systematic review of systemic medications for the treatment of melasma
Linghong Zhou
University of Ottawa, Canada
Background & Aim: Melasma is a common disorder of pigmentation affecting people with darker skin types, most commonly
Fitzpatrick skin types III-IV. Despite the large variety of treatment options available including solar exposure prevention, topical
lightening agents, chemical peels, light-based and laser therapies, none have shown effective and sustained results, making melasma
a challenging and difficult-to-treat condition. Recently, there has been increasing interest in systemic medications in the treatment of
melasma. This systematic review evaluates the current state of evidence of these systemic medications in terms of efficacy and safety/
tolerability in the treatment of melasma.
Methods: Multiple databases were systematically searched for randomized clinical trials (RCTs) evaluating the use of systemic
medications for the treatment of melasma. A study was excluded if it did not satisfy RCT requirements, did not include melasma
patients, did not report melasma specific outcome measures or consisted of fewer than 10 subjects.
Results: Initial search yielded 629 papers evaluating a variety of treatments for melasma.After the application of inclusion and
exclusion criteria, a total of 8 studies met eligibility criteria. Systemic medications evaluated include tranexamic acid (TA), Polypodium
leucotomos extract (PLE), beta-carotenoid, melatonin and procyanidin. These agents have a generally beneficial effect with a minimal
number and severity of adverse effects.
Conclusion: Oral medications have been shown to be efficacious, safe and well-tolerated in the treatment of melasma. We recommend
that dermatologists introduce systematic medications to their armamentarium for the treatment of melasma.
J Infect Dis Ther 2016, 4:7(Suppl)